Intellia Therapeutics, Inc
NTLAIntellia Therapeutics, Inc. is a biotechnology company focused on developing gene-editing therapies using CRISPR-Cas9 technology. Founded to advance precise genetic modifications for treating genetic diseases and other medical conditions, the company aims to deliver transformative medicines through both in vivo and ex vivo approaches.
Company News
The global gene editing market is projected to grow from $11.29 billion in 2025 to $42.13 billion by 2034, with a CAGR of 15.76%. North America dominates the market, while CRISPR-Cas9 technology leads in market share. Key drivers include potential medical and agricultural applications.
Intellia Therapeutics, a biotech company developing gene-editing therapies for rare diseases, faces significant risks after pausing clinical trials due to a patient experiencing liver damage. Despite potential blockbuster drug candidates, the stock's future remains uncertain.
Intellia Therapeutics reported positive Phase 1 trial results for its gene editing therapy nex-z, showing sustained transthyretin protein reductions and potential clinical improvements in patients with hereditary ATTR amyloidosis. The company expects to complete Phase 3 trial enrollment in 2026 and potentially file for biologics license by 2028.
Analysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.
Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.
